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AbsTRACT
Objective evaluate the efficacy and safety of dual 
neutralisation of interleukin (il)-17a and il-17F 
with bimekizumab, a monoclonal igG1 antibody, in 
addition to certolizumab pegol (CZP) in patients with 
rheumatoid arthritis (Ra) and inadequate response (iR) 
to certolizumab pegol.
Methods During this phase 2a, double-blind, proof-
of-concept (PoC) study (nCT02430909), patients with 
moderate-to-severe Ra received open-label CZP 400 mg 
at Weeks 0, 2 and 4, and 200 mg at Week 6. Patients 
with iR at Week 8 (Disease activity score 28-joint count 
C-reactive protein (Das28(CRP))>3.2) were randomised 
2:1 to CZP (200 mg every 2 weeks (Q2W)) plus 
bimekizumab (240 mg loading dose then 120 mg Q2W) 
or CZP plus placebo. The primary efficacy and safety 
variables were change in Das28(CRP) between Weeks 
8 and 20 and incidence of treatment-emergent adverse 
events (Teaes).
Results Of 159 patients enrolled, 79 had iR at Week 8 
and were randomised to CZP plus bimekizumab (n=52) 
or CZP plus placebo (n=27). at Week 20, there was a 
greater reduction in Das28(CRP) in the CZP-iR plus 
bimekizumab group compared with the CZP-iR plus 
placebo group (99.4% posterior probability). The most 
frequent Teaes were infections and infestations (CZP 
plus bimekizumab, 50.0% (26/52); CZP plus placebo, 
22.2% (6/27)).
Conclusions PoC was confirmed based on the rapid 
decrease in disease activity achieved with 12 weeks of CZP 
plus bimekizumab. no unexpected or new safety signals 
were identified when neutralising il-17a and il-17F in 
patients with Ra concomitantly treated with CZP, but the 
rate of Teaes was higher with dual inhibition.
InTROduCTIOn
It is well documented that some patients with 
rheumatoid arthritis (RA), particularly those 
with poor prognostic factors, have an inadequate 
response (IR) to initial treatment with conventional 
synthetic disease-modifying antirheumatic drugs 
(csDMARDs), such as methotrexate (MTX). In 
these individuals, add-on treatment with tumour 
necrosis factor (TNF) inhibitors (anti-TNFs) is 
often considered.1 As a class, anti-TNFs (adalim-
umab, certolizumab pegol, etanercept, golimumab 
and infliximab) comprise an effective treatment 
approach that has considerably improved the 
success of treatment for RA.2 3 However, sustained 
disease remission is only achieved by <10% of 
patients, and there remains a group of patients 
who fail to respond, or do not achieve an adequate 
response, even with anti-TNFs.4 Should patients fail 
to respond to one anti-TNF, they may be treated 
with another anti-TNF or a treatment with a 
different mode of action.1
Key messages
What is already known about this subject?
 ► Significant increases in circulating T helper 17 
cells and interleukin (IL)-17 production have 
been observed following inadequate response 
to tumour necrosis factor (TNF) inhibitors (anti-
TNFs) in patients with rheumatoid arthritis.
 ► It has been hypothesised that this 
compensatory amplification of IL-17 biology 
may contribute to the impaired response to 
anti-TNF treatment in some patients; however, 
clinical data substantiating this hypothesis are 
conflicting.
What does this study add?
 ► We evaluated the efficacy and safety of dual 
neutralisation of IL-17A and IL-17F with 
bimekizumab, a monoclonal IgG1 antibody, in 
addition to certolizumab pegol in patients with 
rheumatoid arthritis and inadequate response 
to certolizumab pegol.
 ► Proof-of-concept was confirmed based on the 
rapid decrease in disease activity achieved 
with 12 weeks of certolizumab pegol and 
bimekizumab treatment, with no unexpected or 
new safety findings identified.
How might this impact on clinical practice or 
future developments?
 ► These findings support the potential to further 
explore concomitant neutralisation of multiple 
pathways in other patient populations where 
this treatment strategy may provide additional 
benefits.
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Figure 1 Study design. DAS28(CRP), Disease Activity Score 28-joint count (C-reactive protein); Q2W, once every 2 weeks.
Significant increases in circulating T helper 17 (Th17) cells and 
interleukin (IL)-17 production have been observed following IR 
to anti-TNFs in patients with RA.5–8 It has been hypothesised 
that this compensatory amplification of IL-17 biology may 
contribute to the impaired response to anti-TNF treatment in 
some patients; however, clinical data substantiating this hypoth-
esis are conflicting. For example, phase 3 studies have shown 
that IL-17A blockade with secukinumab has minimal efficacy in 
patients with RA who have IR or intolerance to anti-TNFs,9–11 
suggesting inhibition of IL-17A alone is insufficient to neutralise 
the inflammatory response in RA. Conversely, a phase 2 study 
demonstrated a modest but statistically greater American College 
of Rheumatology 20% improvement criteria (ACR20) response 
with ixekizumab, another higher affinity anti-IL-17A, compared 
with placebo after 12 weeks’ treatment in patients with RA with 
IR to anti-TNF therapy.12
In addition to IL-17A, Th17 cells secrete a number of 
pro-inflammatory cytokines including IL-22, IL-26, interferon 
(IFN)-γ, TNF, granulocyte-macrophage colony-stimulating factor, 
C-C motif chemokine ligand 20 and another member of the IL-17 
family, IL-17F.13 Both IL-17A and IL-17F have been shown to 
independently co-operate with other cytokines to mediate chronic 
inflammation14; they share ~50% structural homology and over-
lapping but non-redundant biological functions,15–17 suggesting 
IL-17F may also play an important role in RA. Bimekizumab is 
a monoclonal immunoglobulin G1 antibody that potently and 
selectively neutralises the biological function of both IL-17A 
and IL-17F.18 In a proof-of-concept (PoC) study in patients with 
psoriatic arthritis, bimekizumab demonstrated rapid, profound 
responses in joint and skin, with no unexpected safety findings.18 In 
the phase 2b BE ABLE 1 study, rapid and substantial improvements 
were achieved with bimekizumab in patients with moderate-to-se-
vere psoriasis.19 These data support the rationale for targeting both 
IL-17A and IL-17F in immune-mediated inflammatory disease. 
For those patients with RA and IR to anti-TNFs, neutralisation of 
both IL-17A and IL-17F in addition to TNF inhibition may reduce 
disease activity compared with inhibition of TNF alone. However, 
the potential safety effects of inhibiting these three cytokines 
together are not known.
Here, we report the efficacy and safety results of a phase 
2a, randomised, double-blind, placebo-controlled PoC study 
(NCT02430909) evaluating certolizumab pegol, a Fc-free, 
PEGylated anti-TNF that provides rapid and sustained improve-
ments to many patients with RA,20 21 in combination with bime-
kizumab in patients with moderate-to-severe RA who had an IR 
to certolizumab pegol.
MeTHOds
study design and treatment
This was a multicentre phase 2a, randomised, double-blind, 
placebo-controlled PoC study (NCT02430909) to assess the 
efficacy and safety of certolizumab pegol plus bimekizumab in 
patients with moderate-to-severe RA and IR to certolizumab 
pegol. This study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and the International 
Conference on Harmonisation Guidance for Good Clinical 
Practice. Independent institutional review board approvals were 
obtained, and all patients provided written informed consent in 
accordance with local requirements.
During an 8-week open-label, run-in period, patients received 
certolizumab pegol 400 mg at Weeks 0, 2 and 4, and then 200 mg 
at Week 6 (figure 1). Patients who responded to certolizumab pegol 
during the open-label run-in period remained on this treatment. 
Patients with IR to certolizumab pegol at Week 8, defined as Disease 
Activity Score 28-joint count C-reactive protein (DAS28(CRP)) 
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Figure 2 Patient disposition. *Inadequate response was defined as Disease Activity Score 28-joint count (C-reactive protein) >3.2. IR, inadequate 
response.
>3.2, were randomised 2:1 to certolizumab pegol (200 mg every 
2 weeks (Q2W)) plus bimekizumab (240 mg loading dose then 120 
mg Q2W) or certolizumab pegol (200 mg Q2W) plus placebo. At 
Week 20, the add-on therapy (bimekizumab or placebo) was with-
drawn; certolizumab pegol continued until Week 32, after which 
their treatment was determined by their clinician outside of the 
study protocol. There was a final follow-up visit at Week 44, 12 
weeks after the end of study treatment.
Patients
Patients were aged 18–69 years with a diagnosis of adult-onset 
moderate-to-severe RA of ≥6 months’ duration as defined by 
ACR/European League Against Rheumatism 2010 classification 
criteria.22 Additional inclusion criteria were body mass index 
18–35 kg/m2, with a body weight of ≥50 kg (men) or 45 kg 
(women); ≥6 tender joints (out of 68), ≥6 swollen joints (out 
of 66) and ≥10 mg/L CRP; and IR to ≥1 csDMARD. Patients 
with IR to csDMARDs could continue on stable doses of any 
permitted csDMARD; patients with a history of IR, but not 
currently receiving csDMARDS, were also eligible.
Key exclusion criteria were previous exposure to anti-TNFs, 
IL-17 inhibitors or bimekizumab; receipt of any investigational 
drug or experimental procedure within 90 days prior to baseline; 
and receipt of prohibited medications (online supplementary 
table S1). Patients with an active/high risk of infection, active or 
latent tuberculosis, known central nervous system demyelinating 
disorder or neoplastic disease within 5 years of study entry (with 
the exception of definitively treated basal or squamous carci-
noma of the skin or carcinoma in situ) were excluded.
Assessments
The primary efficacy endpoint was change in DAS28(CRP) 
between Weeks 8 and 20. Secondary efficacy endpoints were 
DAS28(CRP) remission (DAS28(CRP)<2.6) at Week 20, 
percentage of improvement in ACR criteria (ACRn), ACR20, 
ACR50 and ACR70 response between Weeks 8 and 20. 
DAS28(CRP) remission by visit was an exploratory endpoint. 
The primary safety endpoint was the incidence of adverse events 
(AEs) at follow-up (Week 44); results of clinical laboratory tests 
was an additional safety endpoint. Treatment-emergent AEs 
(TEAEs) that occurred during treatment with either bimeki-
zumab or placebo were defined as any AE that started or wors-
ened on or after the first dose of bimekizumab or placebo, up to 
140 days after the last dose.
statistical methods
The primary and secondary efficacy endpoints were anal-
ysed using a Bayesian approach. At the design and analysis 
stage, an informative prior23 (equivalent to approximately 13 
patients) was assumed for the primary endpoint; this allowed 
for information borrowing from a previous study21 to augment 
the control data from the certolizumab pegol-IR plus placebo 
group (online supplementary methods). A Bayesian analysis of 
covariance was conducted with treatment as factor and Week 8 
DAS28(CRP) as covariate. In addition, several sensitivity anal-
yses were conducted for the primary efficacy endpoint (online 
supplementary methods). The change from Week 8 in the indi-
vidual components of DAS28(CRP) at Week 20 was summarised 
for each treatment group using descriptive statistics. Addi-
tional analyses included Boolean, DAS28(CRP)[3] and Clinical 
Disease Activity Index (CDAI) remission (online supplementary 
methods). A Bayesian analysis using a logistic model with vague 
prior distributions was conducted for the secondary efficacy 
variables (DAS28(CRP) remission, ACRn, ACR20, ACR50 and 
ACR70 response). These endpoints were plotted over time by 
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Table 1 Demographics and baseline disease characteristics
Certolizumab 
pegol–IR plus 
bimekizumab
(n=52)
Certolizumab 
pegol–IR plus 
placebo
(n=27)
Certolizumab 
pegol 
responders
(n=80)
Demographics, n (%)
Age, median (range), years 53 (26–69) 57 (30–67) 58 (21–69)
Gender
  Male 7 (13.5) 4 (14.8) 13 (16.3)
  Female 45 (86.5) 23 (85.2) 67 (83.8)
Race
  Caucasian 52 (100) 27 (100) 80 (100)
Duration of RA
  <2 years 12 (23.1) 8 (29.6) 17 (21.3)
  ≥2 years 40 (76.9) 19 (70.4) 63 (78.8)
History of extra-articular 
features
7 (13.5) 1 (3.7) 7 (8.8)
Anti-CCP positive 39 (75) 19 (70.4) 66 (82.5)
Rheumatoid factor positive 39 (75) 22 (81.5) 64 (80.0)
Prior csDMARDs* 49 (94.2) 27 (100) 79 (98.8)
  Methotrexate 43 (82.7) 22 (81.5) 76 (95)
  Methotrexate sodium 6 (11.5) 4 (14.8) 5 (6.3)
Concomitant csDMARDs† 42 (80.8) 26 (96.3) 71 (88.8)
  Methotrexate 29 (55.8) 20 (74.1) 63 (78.8)
  Methotrexate sodium 6 (11.5) 3 (11.1) 3 (3.8)
Disease characteristics, mean (SD)
  SJC‡ 13.6 (6.4) 16.2 (7.9) 11.1 (5.4)
  TJC‡ 20.6 (10.5) 26.2 (12.3) 20.3 (9.8)
  PtAAP 72.9 (15.5) 73.1 (17.8) 63.2 (21.4)
  PtGADA 74 (14.2) 77.7 (17) 64.3 (20.9)
  HAQ-DI 1.7 (0.6) 1.9 (0.4) 1.6 (0.6)
  DAS28(CRP) 6.1 (0.7) 6.2 (0.8) 5.7 (0.8)
All patients received certolizumab pegol during the 8-week open-label run-in 
period.
*Prior medications include any medications that started prior to the start date of 
study medication.
†Concomitant medications are medications taken at least 1 day in common 
with the study medication, ie, whose start date is prior to the date of last study 
medication administration plus 14 days, and whose stop date is either missing, or 
on or after the date of first study medication administration.
‡SJC and TJC were based on 66 and 68 counts, respectively.
Anti-CCP, anti-cyclic citrullinated peptide; csDMARD, conventional synthetic disease-
modifying antirheumatic drug; DAS28(CRP), Disease Activity Score 28-joint count 
(C-reactive protein); HAQ-DI, Health Assessment Questionnaire–Disability Index; 
PtAAP, Patient’s Assessment of Arthritis Pain; PtGADA, Patient’s Global Assessment 
of Disease Activity; RA, rheumatoid arthritis; SCJ, swollen joint count; TJC, tender/
painful joint count.
treatment group including the 95% confidence interval (CI) 
using a Wilson approximation.
Sample size calculations were based on a Bayesian analysis of 
the primary endpoint (online supplementary methods). A sample 
size of 60 patients across both treatment groups was deemed 
sufficient to determine the primary endpoint success criterion of 
the ≥97.5% probability that the change in DAS28(CRP) from 
Week 8 was greater for the certolizumab pegol-IR plus bime-
kizumab group than the certolizumab pegol-IR plus placebo 
group. The study had an 89% probability of detecting a differ-
ence of 0.7 in DAS28(CRP) change from Week 8 between the 
treatment groups at Week 20.
All analyses were performed using SAS V.9.3 or later, R 
V.2.10.1 or later, or WinBUGS V.1.4.
ResulTs
Patients
Of 159 patients enrolled, 79 had IR to certolizumab pegol at Week 
8 and were randomised to certolizumab pegol plus bimekizumab 
(n=52) or certolizumab pegol plus placebo (n=27) (figure 2). 
Patients who achieved low disease activity (DAS28(CRP)≤3.2; 
n=80) at Week 8 continued to receive open-label certolizumab 
pegol.
At baseline, demographics and disease characteristics were 
similar between the certolizumab pegol-IR plus bimekizumab 
group and the certolizumab pegol-IR plus placebo group 
(table 1). Disease characteristics at randomisation (Week 8; 
online supplementary table S2) were also similar between 
groups, although Patient’s Assessment of Arthritis Pain and 
Patient’s Global Assessment of Disease Activity (PtGADA) were 
numerically higher in the certolizumab pegol-IR plus bimeki-
zumab group (53.4% and 53.7%, respectively) compared with 
the certolizumab pegol-IR plus placebo group (46% and 45.6%, 
respectively). Most patients received concomitant csDMARDs 
(80.8% in the certolizumab pegol-IR plus bimekizumab group 
and 96.3% in the certolizumab pegol-IR plus placebo group) 
(table 1). Demographics and characteristics for the certolizumab 
pegol responders group are also detailed in table 1.
efficacy
PoC was confirmed based on the primary efficacy endpoint, 
with a greater reduction in DAS28(CRP) in the certolizumab 
pegol-IR plus bimekizumab group compared with the certoli-
zumab pegol-IR plus placebo group from Week 8 to Week 20 
(99.4% posterior probability by Bayesian analysis using an infor-
mative prior distribution). The estimated posterior group mean 
DAS28(CRP) change from Week 8 to Week 20 for the certoli-
zumab pegol-IR plus bimekizumab group and the certolizumab 
pegol-IR plus placebo group were -1.41 (95% credible interval 
(CrI) -1.72, 1.09) and -0.82 (95% CrI -1.15, 0.49), respectively, 
with an estimated posterior mean treatment difference of 0.58 
(95% CrI 0.13, 1.05). The results of sensitivity analyses of the 
primary efficacy variable were consistent with and supportive of 
the primary analysis (online supplementary results). The observed 
mean (SD) change from Week 8 to Week 20 in DAS28(CRP) 
was -1.40 (1.32) in the certolizumab pegol-IR plus bimeki-
zumab group and -1.04 (0.90) in the certolizumab pegol-IR plus 
placebo group.
At Week 20, a greater percentage of patients in the certoli-
zumab pegol-IR plus bimekizumab group achieved DAS28(CRP) 
remission compared with the certolizumab pegol-IR plus 
placebo group (97.6% posterior probability); the estimated 
posterior mean treatment difference in DAS28(CRP) remission 
was 17.8% (95% CrI 0.3, 33.8). The percentage of patients 
achieving DAS28(CRP) remission in the certolizumab pegol-IR 
plus bimekizumab group and the certolizumab-IR plus placebo 
group was similar during Weeks 2 to 8, and numerically higher 
during Weeks 10 to 26. By Week 32, after a further 12 weeks 
of certolizumab pegol treatment without the add-on therapy 
(bimekizumab or placebo), the percentage of patients achieving 
DAS28(CRP) remission was similar between the certolizumab 
pegol-IR plus bimekizumab group and certolizumab pegol-IR 
plus placebo group (figure 3A and online supplementary table 
S5).
Analysis of the DAS28(CRP) components showed numerically 
larger reductions in mean swollen joint count (SJC) and tender 
joint count (TJC) in the certolizumab pegol-IR plus placebo 
group from Week 8 to Weeks 20 and 32 compared with the 
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Figure 3 DAS28(CRP) remission by visit (A), percentage of ACR20 (B), ACR50 (C) and ACR70 (D) responders based on Week 8 in the certolizumab 
pegol-IR plus bimekizumab and certolizumab pegol-IR plus placebo groups. At Week 20, the add-on therapy (bimekizumab or placebo) was 
withdrawn; certolizumab pegol continued until Week 32. All patients continued certolizumab pegol therapy until Week 32, after which their treatment 
was determined by their clinician outside of the study protocol. There was a final follow-up visit at Week 44. See online supplementary table S5 for 
actual data. Error bars represent Wilson’s 95% CI. ACR20, ACR50, ACR70, American College of Rheumatology 20%, 50% and 70% improvement 
criteria; DAS28(CRP), Disease Activity Score 28-joint count (C-reactive protein).
Table 2 DAS28(CRP) and ACR response rates at weeks 20 and 32
Certolizumab pegol–
IR plus bimekizumab
(n=52)
Certolizumab 
pegol–IR 
plus placebo
(n=27)
DAS28(CRP) <3.2, n (%)
  Week 20 21 (45.7) 7 (29.2)
  Week 32 26 (60.5) 11 (47.8)
ACR20, n (%)
  Week 20 26 (60.5) 13 (54.2)
  Week 32 25 (62.5) 15 (65.2)
ACR50, n (%)
  Week 20 15 (34.9) 2 (8.3)
  Week 32 16 (40.0) 6 (26.1)
ACR70, n (%)
  Week 20 6 (14.0) 0
  Week 32 11 (27.5) 5 (21.7)
ACR20, ACR50, ACR70, American College of Rheumatology 20%, 50% and 70% 
improvement criteria.
DAS28(CRP), Disease Activity Score 28-joint count (C-reactive protein).
certolizumab pegol-IR plus bimekizumab group; conversely, 
mean reductions in PtGADA were numerically greater in the 
certolizumab pegol-IR plus bimekizumab group (online supple-
mentary table S3). Results of additional efficacy endpoints 
(including Boolean, DAS28(CRP)[3] and CDAI remission) are 
presented in online supplementary table S4.
The posterior probability of improvement in ACRn in the 
certolizumab pegol-IR plus bimekizumab group compared 
with the certolizumab pegol-IR plus placebo group at Week 20 
was 70.6%; the estimated posterior mean treatment difference 
in ACRn was 5.38 (95% Crl -13.8, 25.3). Results of Bayesian 
analysis of ACR20, ACR50 and ACR70 response are detailed in 
online supplementary results; percentage of ACR20, ACR50 and 
ACR70 responders by visit is shown in figure 3, online supple-
mentary table S5 and table 2.
safety
Mean durations of exposure for the certolizumab pegol-IR plus 
bimekizumab group and the certolizumab pegol-IR plus placebo 
group were similar (80.1 days vs 78.3 days, respectively). Across 
all parts of the study, the mean duration of exposure for certoli-
zumab pegol was 205.8 days. A greater percentage of patients 
experienced TEAEs with certolizumab pegol plus bimekizumab 
compared with certolizumab pegol plus placebo (78.8% (41/52) 
vs 59.3% (16/27)) (table 3). Severe TEAEs were reported for one 
patient in each treatment group (one patient in the certolizumab 
pegol-IR plus bimekizumab group experienced haematoma and 
psoas abscess; one patient in the certolizumab pegol-IR plus 
placebo group experienced meningitis). There were no deaths in 
the certolizumab pegol-IR plus bimekizumab group; one patient 
in the certolizumab pegol-IR plus placebo group experienced a 
TEAE resulting in death (meningitis).
The most frequent TEAEs were infections and infestations, 
with a higher incidence seen with certolizumab pegol plus bime-
kizumab (50.0% (26/52)) compared with certolizumab pegol 
plus placebo (22.2% (6/27)). The most common non-serious 
infections reported by ≥5% of patients in either group were 
nasopharyngitis, upper respiratory tract infection and pharyngitis 
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Table 3 TEAEs during certolizumab pegol plus bimekizumab and 
certolizumab pegol plus placebo treatment
Variable, n (%)*
Certolizumab 
pegol–IR plus 
bimekizumab
(n=52)
Certolizumab 
pegol–IR plus 
placebo
(n=27)
Any TEAE 41 (78.8) 16 (59.3)
Serious TEAEs 2 (3.8) 3 (11.1)
Discontinuation due to TEAEs 4 (7.7) 3 (11.1)
Severe TEAEs 1 (1.9) 1 (3.7)
Deaths 0 1 (3.7)
Most common TEAEs by SOC and PT (reported in ≥5% of patients)
Infections and infestations 26 (50.0) 6 (22.2)
  Nasopharyngitis 4 (7.7) 2 (7.4)
  Upper respiratory tract infection 3 (5.8) 1 (3.7)
  Pharyngitis 3 (5.8) 0 (0.0)
Musculoskeletal and connective tissue 
disorders
5 (9.6) 7 (25.9)
  Rheumatoid arthritis 3 (5.8) 4 (14.8)
Skin and subcutaneous disorders 8 (15.4) 1 (3.7)
  Dermatitis allergic 3 (5.8) 0 (0.0)
Gastrointestinal disorders 6 (11.5) 1 (3.7)
  Stomatitis 3 (5.8) 0 (0.0)
General disorders and administration site 
reactions
4 (7.7) 1 (3.7)
Investigations 4 (7.7) 1 (3.7)
Vascular disorders 2 (3.8) 3 (11.1)
  Hypertension 0 (0.0) 3 (11.1)
Blood and lymphatic system disorders 3 (5.8) 0 (0.0)
Injury, poisoning and procedural 
complications
1 (1.9) 2 (7.4)
TEAEs during treatment were defined as an adverse event that started or worsened 
on or after the first dose of bimekizumab or placebo up to 140 days after the final 
dose. TEAEs were coded using MedDRA V.19.0.
*n=number of patients reporting at least one TEAE within the SOC/PT.
csDMARD, conventional synthetic disease-modifying antirheumatic drug; PT, 
preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event.
(table 3). Skin and subcutaneous disorders and gastrointestinal 
disorders also occurred with a higher incidence in the certoli-
zumab pegol plus bimekizumab group compared with certoli-
zumab pegol plus placebo. Eight patients in the certolizumab 
pegol plus bimekizumab group reported nine skin and subcuta-
neous TEAEs, including three of allergic dermatitis, two of rash 
(both reported by the same patient) and one each of photosen-
sitivity reaction, dermatitis, atopic dermatitis and skin lesion. 
Six patients reported eight gastrointestinal disorder TEAEs with 
certolizumab pegol plus bimekizumab, which included three 
TEAEs of stomatitis, two of dry mouth and one each of diar-
rhoea, dysphagia and tongue geographic.
Serious infections were experienced by one patient in the 
certolizumab pegol-IR plus bimekizumab group (psoas abscess 
98 days after final bimekizumab dose) and one patient in the 
certolizumab pegol-IR plus placebo group (meningitis leading to 
death, 89 days after last placebo dose); both were considered 
unrelated to study treatment by the investigator.
Treatment-emergent grade 3 low neutrophil values were expe-
rienced by three patients (5.8%) in the certolizumab pegol-IR 
plus bimekizumab group and one patient (3.7%) in the certoli-
zumab pegol-IR plus placebo. In most patients, this was a tran-
sient event that resolved and patients remained on treatment; one 
patient in the certolizumab pegol-IR plus bimekizumab group 
withdrew from the study. No additional patterns of change in 
any laboratory parameters were identified.
Overall, the safety profile for certolizumab pegol plus bimeki-
zumab was consistent with previous findings for bimekizumab. 
The safety profile in the certolizumab pegol responders group 
(online supplementary results, online supplementary table S6) 
was also consistent with the known safety profile of certoli-
zumab pegol.24
dIsCussIOn
This study tested the principle of enhancing an IR to an anti-TNF 
therapy, in this case certolizumab pegol, by the addition of 
another treatment, in this case bimekizumab. The primary 
endpoint for the study was met, with a greater reduction in 
DAS28(CRP) in the certolizumab pegol-IR plus bimekizumab 
group at Week 20, compared with the certolizumab pegol-IR plus 
placebo group. Treatment with certolizumab pegol plus bimeki-
zumab was also associated with a greater percentage of patients 
achieving DAS28(CRP) remission at Week 20 compared with 
certolizumab pegol plus placebo. Secondary efficacy outcomes, 
such as ACR50 and ACR70 at Week 20, also showed evidence 
for greater benefit with certolizumab pegol plus bimekizumab 
compared with certolizumab pegol plus placebo.
DAS28(CRP) response in the certolizumab pegol plus bime-
kizumab group was maintained for an additional 24 weeks of 
treatment with certolizumab pegol. Clinical response to certoli-
zumab pegol is usually achieved within 12 weeks of treatment24; 
however, the certolizumab pegol-IR plus placebo group showed 
continued gradual improvement, such that by Week 32 the 
improvements reached were similar to the certolizumab pegol-IR 
plus bimekizumab group. Further work is required to determine 
whether treatment with certolizumab pegol plus bimekizumab 
for 12 weeks was sufficient to downregulate the inflammatory 
response to a level that could be maintained once treatment with 
bimekizumab was withdrawn. In addition, changes to individual 
components of the DAS28(CRP) suggested that improvements 
in the certolizumab pegol-IR plus bimekizumab group may 
have been mostly attributable to changes in PtGADA, with little 
impact of the combined treatment on SJC or TJC. It is notable 
that this group had a markedly higher baseline PtGADA score at 
randomisation.
In contrast to our findings, a recent study found no difference 
in efficacy with dual inhibition of TNF and IL-17A with ABT-122 
compared with inhibition of TNF alone with adalimumab.25 
However, patients in this study were anti-TNF naïve whereas 
patients in our study demonstrated IR to anti-TNF treatment. 
The difference in efficacy may also be attributable to the differ-
ence in IL-17 inhibition: ABT-122 inhibits IL-17A but bimeki-
zumab inhibits both IL-17A and IL-17F. Any potential gains in 
efficacy as a result of targeting two inflammatory pathways must 
be considered in balance with associated risks. Indeed, previous 
attempts to combine anti-TNF therapy with other modulators 
of the immune response, for example, etanercept plus abatacept 
(CTLA-4Ig) and etanercept plus anakinra (IL-1R antagonist), 
have resulted in increased safety risks, including increased rates 
of infection in patients with RA.26 27 The safety profile of certoli-
zumab pegol plus bimekizumab in this study was consistent with 
that expected in patients receiving certolizumab pegol for RA21 
and patients with psoriasis or psoriatic arthritis receiving bime-
kizumab.18 19 There were no unexpected safety findings specifi-
cally associated with the combination of certolizumab pegol and 
bimekizumab. Of note, the incidence of infections and infes-
tations in the certolizumab pegol-IR plus bimekizumab group 
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was over double that of the certolizumab pegol-IR plus placebo 
group (50% vs 22.2%). This was not due to an increased rate of 
any particular AE; nasopharyngitis and upper respiratory tract 
were the most common infections, with similar incidence in both 
treatment groups.
There is evidence to suggest that a higher baseline frequency 
of Th17 cells is associated with poor response to anti-TNF 
therapy.5–8 The biology underlying the observed rises in Th17 
numbers and IL-17A production after anti-TNF treatment in 
patients with RA is not fully understood. As noted by Hull et 
al, patients with higher baseline frequencies of circulating Th17 
cells may have more IL-17-predominant disease and could 
therefore obtain greater benefit from the combined inhibition 
of IL-17A, IL-17F and TNF.7 However, the study popula-
tion was not large enough to identify any subpopulations that 
may have achieved particular benefit from the combination of 
certolizumab pegol plus bimekizumab. A further limitation of 
this study was that the effect of bimekizumab treatment alone 
was not assessed, including the effect of IL-17 inhibition on 
CRP, independent of clinical activity. In addition, evaluation of 
response to certolizumab pegol after 8 weeks may have resulted 
in initiation of additional treatment with bimekizumab in 
patients who would have met response criteria given additional 
time. The bimekizumab regimen in this study was significantly 
less than the maximum human exposure observed at the time of 
study initiation in patients with mild psoriasis (640 mg).28 This 
was to allow for the different study population and any possible 
drug−drug interactions that might have increased exposure to 
bimekizumab; the dose regimen used for certolizumab pegol is 
an approved dose regimen in patients with RA.24
A rapid increase in response was achieved with 12 weeks of 
certolizumab pegol plus bimekizumab in patients with IR to 
certolizumab pegol. Neutralising both IL-17A and IL-17F in 
patients with moderate-to-severe RA treated with certolizumab 
pegol and background csDMARDs did not give rise to unex-
pected or new safety signals, although the rate of TEAEs was 
higher with dual inhibition. Overall, these findings support 
the potential to further explore concomitant neutralisation of 
multiple pathways in other patient populations where this treat-
ment strategy may provide additional benefits.
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